Home > Boards > US Listed > Biotechs > Arena Pharmaceuticals, Inc. (ARNA)

The news out after hours is a big one!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
stockhero Member Profile
 
Followed By 18
Posts 2,520
Boards Moderated 0
Alias Born 12/29/07
160x600 placeholder
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease ... PR Newswire (US) - 10/18/2019 3:01:00 AM
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease ... PR Newswire (US) - 10/18/2019 3:01:00 AM
Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology... PR Newswire (US) - 9/26/2019 8:30:00 AM
Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2 PR Newswire (US) - 9/25/2019 8:30:00 AM
Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologi... PR Newswire (US) - 9/17/2019 8:30:00 AM
Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterol... PR Newswire (US) - 9/9/2019 8:30:00 AM
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire (US) - 8/28/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 6:06:04 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:06:22 PM
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and ... PR Newswire (US) - 8/7/2019 4:01:00 PM
Arena Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on August 7 PR Newswire (US) - 7/31/2019 8:30:00 AM
Arena Pharmaceuticals Announces First Subject Dosed in CAPTIVATE Phase 2 Trial Evaluating Olorinab in Abdominal Pain Associat... PR Newswire (US) - 7/25/2019 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/20/2019 7:00:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:57:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:54:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:52:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:49:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:47:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:44:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:42:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 6:39:53 PM
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative ... PR Newswire (US) - 6/17/2019 8:30:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/14/2019 4:52:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:18:37 PM
Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19 PR Newswire (US) - 6/13/2019 8:30:00 AM
stockhero   Monday, 09/24/18 08:11:09 PM
Re: stockhero post# 22617
Post # of 22657 
The news out after hours is a big one!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist